^
Association details:
| Biomarker: | EGFR E746_S752delinsV |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma
Excerpt:
...We analyzed the initial tissue upon which was only found EGFR p.E746_S752delinsV by next-generation sequencing...the patient was administrated erlotinib (150 mg daily) from November 2014 to August 2017. Thus far, no progression of the original lung mass has been identified; however, multiple bone, liver, and adrenal metastases were noted...Hence, we concluded that the patient had EGFR–tyrosine kinase inhibitor (TKI) resistance.
DOI:
10.1016/j.jtho.2018.05.009
